Abstract

BackgroundWhile many studies of effective hereditary angioedema (HAE) therapy have demonstrated improved health-related quality of life (HRQoL) using validated instruments, specific reasons behind the improved scores have never been investigated using qualitative methods. A non-interventional, qualitative research study was designed to investigate the reasons for improvements in HRQoL while using effective prophylaxis, in this case subcutaneous C1INH (C1INH[SC]) replacement therapy.MethodsAdult patients with HAE-C1INH type 1 or 2 who had been using C1INH(SC) for ≥ 3 consecutive months were recruited through four HAE specialty practices in the US to participate in a 60-min phone interview performed by a trained qualitative research specialist (ICON plc) using a semi-structured interview guide with open-ended questions developed with the Angioedema Quality of Life (AE-QoL) items in mind. Interview transcripts were analyzed using thematic analysis methods to identify concepts (specific symptoms/impacts) and themes (higher-level categories grouping related concepts). A cross-mapping exercise was performed between interview-identified concepts and items included in the AE-QoL.ResultsFourteen patients were interviewed and included in the analysis (age range, 28–82 years [mean 47.5 years]; 64% female; 93% white). In 10 interviews, patients mentioned having no or nearly no HAE attacks, no longer feeling limited by HAE, less HAE-related anxiety/worry and depression, an improved ability to travel, fewer emergency room/hospital visits, and ease of administration of C1INH(SC), including not requiring assistance from others. Other commonly expressed concepts included: increased feelings of confidence, independence, optimism, and normalcy; less absence from work/school; better productivity; improved sleep and energy; healthier family relationships; and improved cognition. While all AE-QoL items emerged from patient interviews, a number of identified concepts were not addressed by the AE-QoL, including sensitivity to various potential attack-triggers (e.g., stress/anxiety, sports), attack frequency, not having to cancel social plans, improvements in ability to perform day-to-day tasks, and a lower burden from medical visits.ConclusionsFrom these interviews, a large number of common themes and concepts emerged: a greater sense of freedom and normalcy, increased productivity, and improved interpersonal relationships while using convenient and effective prophylaxis. These findings provide insights into real-world experiences and the many facets of HRQoL that are important to patients with HAE-C1INH.

Highlights

  • While many studies of effective hereditary angioedema (HAE) therapy have demonstrated improved health-related quality of life (HRQoL) using validated instruments, specific reasons behind the improved scores have never been investigated using qualitative methods

  • Anderson et al Allergy Asthma Clin Immunol (2021) 17:60 attack frequency, not having to cancel social plans, improvements in ability to perform day-to-day tasks, and a lower burden from medical visits. From these interviews, a large number of common themes and concepts emerged: a greater sense of freedom and normalcy, increased productivity, and improved interpersonal relationships while using convenient and effective prophylaxis. These findings provide insights into real-world experiences and the many facets of HRQoL that are important to patients with HAE-C1INH

  • Patients Each investigator invited patients to participate in an interview based on the following inclusion/exclusion criteria: patients had to be ≥ 18 years of age; diagnosed with HAE-C1INH type 1 or 2; be a native English speaker with the cognitive, linguistic, and social capacities necessary to participate in a 60-min phone interview; and current use of C1INH(SC) replacement therapy for ≥ 3 consecutive months

Read more

Summary

Introduction

While many studies of effective hereditary angioedema (HAE) therapy have demonstrated improved health-related quality of life (HRQoL) using validated instruments, specific reasons behind the improved scores have never been investigated using qualitative methods. A non-interventional, qualitative research study was designed to investigate the reasons for improvements in HRQoL while using effective prophylaxis, in this case subcutaneous C1INH (C1INH[SC]) replacement therapy. Multiple factors contribute to profound health-related quality of life (HRQoL) burdens in patients with HAE-C1INH, including the chronic, lifelong nature of the disease, the pain and disfigurement that accompanies attacks, anxiety over potentially fatal laryngeal attacks, and disruptions in productivity and social interactions. Medications for treating attacks (on-demand treatment) include intravenously (IV) administered human plasma-derived C1INH ­(Berinert®/ CSL Behring) and recombinant C1INH ­(Ruconest®; Pharming Healthcare) and two subcutaneously (SC) administered products: ecallantide (­Kalbitor®; Shire), a plasma kallikrein inhibitor; and icatibant (­Firazyr®; Shire), a bradykinin B-2 receptor antagonist. Therapies for preventing attacks (prophylaxis) include IV plasmaderived C1INH ­(Cinryze®, Shire), SC plasma-derived C1INH ­(HAEGARDA®, CSL Behring), and the SC monoclonal antibody lanadelumab (TAKHZYROTM/ Takeda [formerly Shire])

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call